management of barrett’s esophagus
Clicks: 122
ID: 163983
2000
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
122 views
11 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #161 of 250 articles by views in indian journal of pharmacology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 250 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
There have been major recent advances in the understanding of the
pathogenesis and epidemiology of Barrett’s esophagus and adenocarcinoma
of the esophagus. The advent of potent acid suppression
with proton pump inhibitors and safe, minimally invasive antireflux
procedures has made alleviating symptoms and eliminating peptic
complications achievable goals for the vast majority of patients. Endoscopic
surveillance of Barrett’s esophagus is considered the standard
of care and is widely used in clinical practice. Neither medical
nor surgical antireflux procedures, however, result in the regression
of Barrett’s esophagus in any consistent manner. Thermal and
chemical endoscopic ablation techniques show promise in both the
management of high grade dysplasia and the reversal of Barrett’s
esophagus, but these techniques are still of unproven benefit, and
can be costly and risky. Therefore, prospective and controlled studies
with long term follow-up are needed before incorporating ablative
techniques into routine clinical practice. Management of high
grade dysplasia remains controversial. Alternative management
strategies include surveillance, resection or ablation, tailored to the
individual patient and the available expertise. Targets for future research
include defining appropriate surveillance intervals; finding
biological markers that identify patients at higher risk of progressing
to cancer; defining the cancer risk and the appropriate management
of patients with short segment Barrett’s esophagus; understanding
the natural history of dysplasia and comparing alternatives for the
management of high grade dysplasia; and studying whether surgical
management can delay or prevent the progression to dysplasia and
adenocarcinoma.
| Reference Key |
younes2000canadianmanagement
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Ziad Younes;Mark D Duncan;John W Harmon |
| Journal | indian journal of pharmacology |
| Year | 2000 |
| DOI |
10.1155/2000/319616
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.